Genmab A/S (GMAB) fair value analysis

Nasdaq · Updated 2026-09-07

Genmab A/S is a Danish biotechnology company that develops and commercializes monoclonal antibody-based therapeutic drugs for the treatment of cancer, autoimmune, and infectious diseases. The company operates globally with research, development, and commercial operations across Europe, North America, and other international markets.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, GMAB is trading at a 10–25% discount to estimated fair value.

GMAB currently ranks #48 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $28.68
Sector: Healthcare
12-month range: $25.45–$33.27

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: A
Leverage: Low
Margin trend: Contracting
Revenue growth: Declining
RSI zone: Neutral
50/200-day trend: Mixed
52-week position: The lower-middle quarter of its range
DCF cross-check: Undervalued

What our data shows for GMAB

Our model validated 17 trailing price-to-earnings windows for GMAB, built from quarterly earnings records.
Shares are trading in the middle of their 12-month price range of $25.45–$33.27.
The 14-day relative strength index sits at a neutral 65.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for GMAB
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent GMAB news

TickrTrends' derived news-sentiment signal for GMAB is currently mixed, computed from recent coverage.

Notice to Convene an Extraordinary General Meeting of Genmab A/S (manilatimes.net, 2026-09-08)
TickrTrends take: Genmab A/S has announced an extraordinary general meeting, an event that typically signals significant corporate developments requiring shareholder approval. Given TickrTrends' current undervalued assessment of the Healthcare sector company, investors focused on valuation metrics should monitor what proposals emerge from this meeting, as such gatherings often involve strategic decisions that could affect the company's financial trajectory and market positioning. The timing and nature of the extraordinary meeting may provide insight into management's capital allocation priorities and future direction relative to the company's current valuation standing.
Genmab to Participate in Upcoming Investor Conferences (manilatimes.net, 2026-08-25)
TickrTrends take: Genmab's participation in upcoming investor conferences provides an opportunity for the market to reassess the company's strategic direction and pipeline progress, which could be relevant given TickrTrends' current undervalued assessment of the Healthcare sector stock. Investors focused on valuation metrics should monitor whether management commentary at these events addresses growth catalysts or operational efficiencies that might validate or challenge the undervalued positioning. Conference presentations often serve as a mechanism for companies to communicate forward-looking developments that could influence how the market prices the stock relative to its fundamentals.
Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab? (insidermonkey.com, 2026-08-13)
TickrTrends take: Genmab faces regulatory scrutiny on epcoritamab, a key asset in its pipeline that could meaningfully impact the company's value creation trajectory. Given TickrTrends' current undervalued assessment of GMAB in the healthcare sector, investors monitoring the stock should track the regulatory outcome closely, as approval or setback would represent a material catalyst affecting the company's commercial prospects and justification for its current valuation. The competitive dynamic with AbbVie adds an additional layer of risk that valuation-focused observers should weigh against GMAB's current pricing.

What people are saying

Follow the GMAB conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is GMAB stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), GMAB is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is GMAB's TickrTrends verdict?

GMAB's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does GMAB compare to other Healthcare stocks?

GMAB ranks #48 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is GMAB overbought or oversold?

GMAB's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

GMAB vs BDX · GMAB vs BTSG · GMAB vs COLL · GMAB vs EW · GMAB vs EXEL